AOD-9604 vs Tesamorelin
Both relate to the growth-hormone axis but in different ways. AOD-9604 is a 16-amino-acid fragment of human growth hormone studied in lipolysis contexts; it is not FDA-approved as a finished product. Tesamorelin is a stabilized GHRH analog with an FDA-approved finished product for an HIV-related visceral adiposity indication. Mechanism, regulatory status, and clinician use cases differ.
What's being compared
16-amino-acid fragment of human growth hormone studied in lipolysis contexts.
Stabilized GHRH analog with an FDA-approved finished product for HIV-related visceral adiposity.
Side-by-side comparison
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Class | GH fragment (peptide). | GHRH analog (peptide). |
| Structure | Modified C-terminal 16-amino-acid fragment of the human growth hormone molecule. | 44-amino-acid GHRH analog with an N-terminal modification that improves stability vs native GHRH. |
| Mechanism in research | Studied for lipolytic signaling without the broader anabolic activity of full-length GH. | Stimulates the patient's own pulsatile growth-hormone release, with downstream rise in IGF-1 in published trials. |
| Effect on the GH axis | Designed to act downstream rather than to drive endogenous GH release; published research has not consistently shown axis-level GH/IGF-1 elevation. | Acts upstream on the axis; published trial program demonstrates measurable changes in GH and IGF-1. |
| Context discussed in the literature | Body-composition and adipose-tissue contexts in animal and earlier-phase human research. | HIV-associated visceral adiposity is the FDA-approved context; clinician practice literature also discusses broader body-composition contexts. |
| Typical schedule | Typically daily subcutaneous injection in clinician-directed compounded protocols. | Daily subcutaneous injection per the labeling and the clinician's protocol. |
| Route | Subcutaneous injection. | Subcutaneous injection. |
| Regulatory status | Not FDA-approved as a finished product; compounded availability is at the discretion of 503A/503B pharmacies and the prescribing clinician. | FDA-approved finished product (Egrifta) exists for HIV-associated visceral adiposity; compounded versions are dispensed by 503A/503B pharmacies and are not FDA-approved. |
| Evidence base | Earlier-phase published trial data and pre-clinical literature; long-term outcomes are not established in the public literature. | Published Phase III trial program supporting the FDA-approved indication; additional clinician practice literature on adjacent contexts. |
| Typical clinician use case | Considered by clinicians who specifically want a GH-fragment approach without driving endogenous GH release. | Considered when a clinician wants to engage the GH axis upstream and the published GH/IGF-1 data is relevant to the patient's situation. |
Which one might fit?
Use the framings below as orientation only. The right therapy is determined by your prescribing clinician based on history, lab work, and the specifics of your situation.
Tesamorelin is the GHRH analog with the largest published axis-level data and an FDA-approved finished product for one indication.
AOD-9604 is the molecule discussed in that context in the published research; it is dispensed only in compounded form after a clinician evaluation.
Both molecules would be off-label or compounded use in that case. The clinician weighs the published evidence, regulatory status, and individual fit before considering either one.
Talk to a clinician about which fits
Every Regen Therapy protocol is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network only after evaluation. Start with a brief intake to see what makes sense for your situation.
Frequently asked questions
Are AOD-9604 and tesamorelin the same kind of molecule?
No. AOD-9604 is a 16-amino-acid fragment of human growth hormone designed to study lipolysis without broader anabolic activity. Tesamorelin is a 44-amino-acid GHRH analog designed to stimulate the patient's own pulsatile GH release. They sit on different points of the growth-hormone axis.
Does AOD-9604 raise growth hormone or IGF-1 levels?
Published research has not consistently shown axis-level elevations of GH or IGF-1 with AOD-9604. The molecule is studied for downstream lipolytic signaling rather than as a GH-axis stimulator.
Is tesamorelin FDA-approved?
Yes, the finished product Egrifta is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Compounded versions of tesamorelin dispensed by 503A or 503B pharmacies are not FDA-approved.
Is AOD-9604 FDA-approved?
No. AOD-9604 is not approved by the FDA as a finished product. It is dispensed only in compounded form by 503A or 503B pharmacies on a patient-specific prescription, after a clinician evaluation.
How are these typically administered?
Both are administered as subcutaneous injections, typically on a daily schedule set by the prescribing clinician.
What does Regen Therapy offer in this category?
AOD-9604 appears in the RT-05 (Retatrutide / MOTS-c / AOD-9604) protocol. Tesamorelin appears in the RT-04 (Tesamorelin / Ipamorelin / MOTS-c) and RT-12 (Tesamorelin / Follistatin) protocols. Each is dispensed by Wells Pharmacy Network when clinically appropriate after evaluation.